OcuMension Therapeutics
IPOPublic · Shanghai, China · Founded 2017
- Headquarters
- Shanghai
- Employees
- 201–500
- Founded
- 2017
- Business Model
- B2C
- Last Round
- Series CJan 2019
- Rounds
- 2
- Type
- Public
About
Ocumension Therapeutics is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing, and commercializing first- or best-in-class treatments for patients suffering from ocular diseases. The company licenses and commercializes eye therapies from global partners, including EyePoint Pharmaceuticals' Durasert products, for the Chinese market, and has entered collaborations such as with Shandong Boan for posterior segment disease treatments. Founded in May 2018 and headquartered in Shanghai, Ocumension is listed on the Hong Kong Stock Exchange (1477.HK).
Summary
OcuMension Therapeutics is a Biotech company based in Shanghai, China, founded in 2017. Its most recent funding was a Series C round in Jan 2019. Investors include Hong Kong Stock Exchange, Temasek and General Atlantic.
Tech & App Stack
1 technologies & apps tracked
Create a free account — 25 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jul 2020
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...